Action of tacrine on muscarinic receptors in rat intestinal smooth muscle.

1. The reversible cholinesterase inhibitor, tacrine (THA) was examined against the contractions of rat duodenum to acetylcholine and carbachol (cholinesterase resistant). 2. Tacrine (10(-6) M) showed a similar behaviour to physostigmine (10(-6) M), changing the characters of the concentration-response curve to Ach. The contractual responses were shifted to the left at low concentrations of ACh to reveal a bell-shaped curve with declaring contradictions at high concentrations of ACh. 3. Antagonism by atropine (10(-8) M) was reduced in the presence of tacrine (10.54, dose-ratio) compared with the shift of the curve in the absence of tacrine (73.9, dose-ratio). The declining phase of the concentration-response curve to ACh was also antagonized by atropine. 4. Further evidence for muscarininc receptor antagonism by tacrine was a small rightward shift of the concentration-response curve for carbachol, an agonist immune to cholinesterase. 5. This study has shown that tacrine acts both as a cholinesterase inhibitor and muscarinic antagonist on rat intestinal smooth muscle.

[1]  L. Parnetti,et al.  Radioligand binding assay of M1–M5 muscarinic cholinergic receptor subtypes in human peripheral blood lymphocytes , 1999, Journal of Neuroimmunology.

[2]  Ş. Oktay,et al.  Subtypes of muscarinic receptors in rat duodenum: a comparison with rabbit vas deferens, rat atria, guinea-pig ileum and gallbladder by using imperialine. , 1999, General pharmacology.

[3]  J. Bizot,et al.  Pharmacological profile of CEB-1957 and atropine toward brain muscarinic receptors and comparative study of their efficacy against sarin poisoning. , 1998, Toxicology and applied pharmacology.

[4]  R. Levin,et al.  Cholinergic Modulation of Electrogenic Ion Transport in Different Regions of the Rat Small Intestine , 1997, The Journal of pharmacy and pharmacology.

[5]  S. Ito,et al.  Tacrine inhibits nicotinic secretory and current responses in adrenal chromaffin cells. , 1997, European Journal of Pharmacology.

[6]  A. Nordberg,et al.  Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors , 1996, Brain Research.

[7]  R. Eglen,et al.  Selective muscarinic receptor agonists and antagonists. , 1996, Pharmacology & toxicology.

[8]  R. Eglen,et al.  Muscarinic acetylcholine receptor subtypes in smooth muscle. , 1994, Trends in pharmacological sciences.

[9]  S. E. Freeman,et al.  Tacrine: A pharmacological review , 1991, Progress in Neurobiology.

[10]  R. Gross,et al.  Tetrahydroaminoacridine (THA) reduces voltage-dependent calcium currents in rat sensory neurons , 1991, Neuroscience Letters.

[11]  R. N. Brogden,et al.  Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease. , 1991, Drugs.

[12]  A. Hunter,et al.  The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro , 1989, British journal of pharmacology.

[13]  D. Mash,et al.  Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine. , 1989, The Journal of pharmacology and experimental therapeutics.

[14]  B. Winblad,et al.  Effects of THA on ionic currents in myelinated axons of Xenopus laevis. , 1989, European journal of pharmacology.

[15]  S. E. Freeman,et al.  Blockade of a cardiac K+ channel by tacrine: interactions with muscarinic and adenosine receptors. , 1988, European journal of pharmacology.

[16]  C. Schauf,et al.  Tetrahydroaminoacridine blocks potassium channels and inhibits sodium inactivation in Myxicola. , 1987, The Journal of pharmacology and experimental therapeutics.

[17]  W. Osterrieder 9‐Amino‐1,2,3,4‐tetrahydroacridine (THA) is a potent blocker of cardiac potassium channels , 1987, British journal of pharmacology.

[18]  M. Rogawski Tetrahydroaminoacridine blocks voltage-dependent ion channels in hippocampal neurons. , 1987, European journal of pharmacology.

[19]  J. C. Lodder,et al.  9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current. , 1987, European journal of pharmacology.

[20]  A. Kling,et al.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.

[21]  N. Birdsall,et al.  Muscarinic receptor subtypes. , 1990, Annual review of pharmacology and toxicology.